货号:GS40720
Tildrakizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the pathogenesis of immune-mediated inflammatory diseases. It binds specifically to IL-23p19, inhibiting its interaction with the IL-23 receptor and downstream signaling. It is approved for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物